Foundations Investment Advisors LLC Boosts Stock Holdings in Gilead Sciences, Inc. $GILD

Foundations Investment Advisors LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 98,745 shares of the biopharmaceutical company’s stock after acquiring an additional 7,603 shares during the period. Foundations Investment Advisors LLC’s holdings in Gilead Sciences were worth $12,120,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of GILD. Brighton Jones LLC grew its stake in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 2,450 shares in the last quarter. Bison Wealth LLC purchased a new position in Gilead Sciences during the fourth quarter valued at $215,000. Sivia Capital Partners LLC grew its stake in Gilead Sciences by 16.8% during the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after acquiring an additional 602 shares in the last quarter. Ieq Capital LLC grew its stake in Gilead Sciences by 12.0% during the second quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock valued at $13,160,000 after acquiring an additional 12,705 shares in the last quarter. Finally, Diversify Advisory Services LLC grew its stake in Gilead Sciences by 18.6% during the second quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock valued at $516,000 after acquiring an additional 674 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a research report on Wednesday, May 20th. Jefferies Financial Group assumed coverage on shares of Gilead Sciences in a research report on Tuesday, March 10th. They set a “buy” rating and a $180.00 price objective for the company. Mizuho increased their price objective on shares of Gilead Sciences from $140.00 to $170.00 and gave the company an “outperform” rating in a research report on Wednesday, February 18th. Needham & Company LLC reiterated a “buy” rating and set a $170.00 price objective on shares of Gilead Sciences in a research report on Monday, February 23rd. Finally, The Goldman Sachs Group increased their price objective on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research report on Friday, April 17th. Twenty-five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $156.93.

Gilead Sciences Price Performance

GILD stock opened at $136.22 on Friday. Gilead Sciences, Inc. has a 52 week low of $104.46 and a 52 week high of $157.29. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The company has a fifty day simple moving average of $135.43 and a two-hundred day simple moving average of $134.08. The firm has a market capitalization of $169.13 billion, a P/E ratio of 18.56 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business’s revenue was up 4.4% on a year-over-year basis. During the same quarter last year, the business earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Analysts anticipate that Gilead Sciences, Inc. will post -0.79 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the sale, the chief financial officer owned 173,191 shares in the company, valued at approximately $22,907,973.57. This trade represents a 1.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the completion of the sale, the chief executive officer owned 632,567 shares of the company’s stock, valued at $81,702,353.72. This trade represents a 1.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 53,000 shares of company stock worth $7,075,670. 0.30% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.